Newer Advances in the Management of Atopic Dermatitis and Role of Phosphodiesterase 4 Inhibitor

Speciality: Dermatology

Description:

A warm welcome to all the medical professionals in this interesting session on Newer Advances in the Management of Atopic Dermatitis and Role of Phosphodiesterase 4 Inhibitor
Newer advances in the management of atopic dermatitis (AD) have introduced innovative therapies that significantly enhance treatment outcomes, especially for those who have not responded well to traditional methods. One of the most notable developments is the use of biologics, such as dupilumab, which specifically target key immune pathways involved in the disease. These biologics have transformed the treatment landscape for moderate to severe AD, offering long-term relief with fewer side effects compared to conventional treatments like topical corticosteroids.
Phosphodiesterase 4 (PDE4) inhibitors, such as crisaborole, represent a significant advancement in treating mild to moderate AD. PDE4 inhibitors work by blocking the enzyme PDE4, which plays a central role in the inflammatory process of AD. By reducing the production of pro-inflammatory cytokines, these inhibitors effectively decrease inflammation and alleviate itching, providing a steroid-free option for patients. Their favorable safety profile makes them suitable for long-term use, including on sensitive skin areas, where steroid use may be limited.
Therefore, get an overall knowledge of newer advances in the management of atopic dermatitis and role of phosphodiesterase 4 Inhibitor
 

See More Webinars @ Hidoc Webinars